Microscopic polyangiitis preceded by combined pulmonary fibrosis and emphysema  by Gocho, Kyoko et al.
lable at ScienceDirect
Respiratory Medicine Case Reports 15 (2015) 128e132Contents lists avaiRespiratory Medicine Case Reports
journal homepage: www.elsevier .com/locate /rmcrCase reportMicroscopic polyangiitis preceded by combined pulmonary ﬁbrosis
and emphysema
Kyoko Gocho a, *, Keishi Sugino a, Keita Sato a, Chikako Hasegawa b, Toshimasa Uekusa c,
Sakae Homma a
a Department of Respiratory Medicine, Toho University Omori Medical Center, 6-11-1, Omori-nishi, Ota-ku, Tokyo 143-8541, Japan
b Department of Pathology, Toho University Omori Medical Center, Japan
c Department of Pathology, Japan Labor Health and Welfare Organization Kanto Rosai Hospital, Japana r t i c l e i n f o
Article history:
Received 27 June 2014
Accepted 23 February 2015
Keywords:
Microscopic polyangiitis
Interstitial lung disease
Emphysema
Combined pulmonary ﬁbrosis
Emphysema* Corresponding author.
E-mail address: kyokogocho@yahoo.co.jp (K. Goch
http://dx.doi.org/10.1016/j.rmcr.2015.02.004
2213-0071/© 2015 The Authors. Published by Elseviera b s t r a c t
A 73-year-old male metalworker was admitted to our hospital with a 3-year history of progressive dry
cough. Chest high-resolution computed tomography revealed emphysematous changes and reticular
lesions, which is referred to as combined pulmonary ﬁbrosis and emphysema (CPFE). Surgical lung bi-
opsy specimens revealed unclassiﬁed interstitial pneumonia, including a nonspeciﬁc interstitial pneu-
monia pattern and usual interstitial pneumonia pattern. Two years after his ﬁrst admission he developed
rapid progressive renal dysfunction with an elevated level of myeloperoxidase-antineutrophil cyto-
plasmic antibody (428 EU). A renal biopsy specimen revealed interstitial nephritis and glomerulone-
phritis. Consequently, microscopic polyangiitis preceded by CPFE was diagnosed. Despite transient
exacerbation of renal involvement, his general condition remained mostly stable during a 2-year period
of corticosteroid treatment. He ultimately died from severe pneumococcal pneumonia associated with
acute lung injury.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Microscopic polyangiitis (MPA) is a systemic necrotizing
vasculitis of the small vessels and is associated with various
circulating autoantibodies, in particular myeloperoxidase-
antineutrophil cytoplasmic antibody (MPO-ANCA). Although
diffuse alveolar hemorrhage secondary to pulmonary capillaritis is
the most frequent manifestation of pulmonary involvement, an
association with pulmonary ﬁbrosis was recently reported. More-
over, oxidation induced by MPO-ANCA may trigger emphysema
and ﬁbrosis. In this report we describe the clinicopathologic ﬁnd-
ings of a case of MPA preceded by combined pulmonary ﬁbrosis and
emphysema (CPFE).
2. Case presentation
A 73-year-old man with a 3-month history of progressive dys-
pnea on exertion and dry cough was referred to our hospital for
treatment. His medical history was noncontributory, and he hado).
Ltd. This is an open access article usmoked for 25 pack-years. His occupational history included metal
work. On admission, his pulse rate was 62/min with regular
rhythm, blood pressure was 120/68 mm Hg, body temperature was
36.0 C, and respiratory rate was 20/min. Chest auscultation
revealed ﬁne crackles in bilateral lung bases. Laboratory analysis
revealed high levels of lactate dehydrogenase (632 IU/L), Krebs von
den Lungen-6 (701 U/mL), surfactant protein-D (195 ng/mL), and
creatinine (1.03 mg/dL); MPO and PR3-ANCA were negative. Uri-
nalysis revealed microscopic hematuria with red blood cells and
proteinuria. Arterial blood gas analysis showed a pH of 7.38, PaCO2
of 38.6 Torr, and PaO2 of 77.8 Torr in room air. Findings from pul-
monary function testing were as follows: vital capacity, 3.3 L
(105.8% of predicted); FEV1, 2.45 L (116.1% of predicted); and
diffusing capacity for carbonmonoxide, 8.51 mL/min/mmHg (59.9%
of predicted). A chest radiograph revealed diffuse reticular shadows
in the bilateral lower lung ﬁelds. A chest computed tomography
(CT) scan showed paraseptal emphysema in the bilateral upper
lobes and reticular lesions with enlarged cysts in the bilateral lower
lobes (Fig. 1). Lung biopsy specimens from the right S6 were ob-
tained by video-assisted thoracoscopic surgery and revealed
prominent, uniform thickening of alveolar septa by ﬁbrosis (ﬁbrotic
nonspeciﬁc interstitial pneumonia [f-NSIP] pattern) (Fig. 2A). Thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Chest computed tomography (CT) scans show paraseptal emphysema in the bilateral upper lobes and reticular lesions with enlarged cysts in the bilateral lower lobes.
Fig. 2. A: Lung biopsy specimens from the right S6 obtained by video-assisted thoracoscopic surgery show prominent uniform thickening of alveolar septa by ﬁbrosis (ﬁbrotic
nonspeciﬁc interstitial pneumonia [f-NSIP] pattern) (EVG stain). B: The alveolar septal thickening mainly consists of collagen deposition with mild inﬂammatory cell inﬁltration and
lymphoid hyperplasia (HE stain).
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with mild inﬂammatory cell inﬁltration and lymphoid hyperplasia
(Fig. 2B). Lung biopsy specimens from the right S8 revealed sub-
pleural and perilobular ﬁbrosis adjacent to relatively normal alveoli
(usual interstitial pneumonia [UIP] pattern) (Fig. 3A). There were
ﬁbroblastic foci with dense collagen ﬁbrosis (Fig. 3B) and smooth
muscle cell proliferation in areas of dense collagen ﬁbrosis (Fig. 3C).
In addition, numerous macrophages with a few eosinophils were
present in the alveolar lumen (DIP-like lesion) (Fig. 4A), and alve-
olar wall destruction with enlargement was seen in lung paren-
chyma (Fig. 4B). Patchy ﬁbrotic lesions were also scattered around
the terminal and respiratory bronchioles (Fig. 4C). There was no
evidence of pulmonary vasculitis. These ﬁndings were consistent
with a diagnosis of CPFE composed of unclassiﬁed interstitial
pneumonia and paraseptal emphysema.
Two years after initial admission, he developed progressive
renal dysfunction with elevated MPO-ANCA level (428 EU). Renal
biopsy specimens revealed interstitial nephritis and glomerulone-
phritis. Ultimately, MPA preceded by CPFE was diagnosed based on
his clinical course and pathologic ﬁndings. He was treated with
prednisolone 30 mg/day, and the dose was tapered based on his
respiratory condition. After beginning treatment, serum MPO-
ANCA titer decreased and hematuria disappeared. When prednis-
olone was tapered to 7.5 mg/day at 1 year after the start of treat-
ment, his serum MPO-ANCA titer increased to 152 EU and he
developed hematuria. Prednisolone dosagewas increased to 15mg/
day, after which serum MPO-ANCA titer normalized but hematuria
continued. During the 4-year treatment period, CPFE had pro-
gressed slowly, with enlargement of paraseptal emphysema in the
upper lobes and prominent reticular shadows without honey-
combing in the lower lobes. Diffusing capacity for carbonmonoxide
had also decreased as emphysema and ﬁbrosis progressed. One
year later, he died of respiratory failure caused by severe pneu-
mococcal pneumonia (Fig. 5).Fig. 3. Lung biopsy specimens from the right S8 showing subpleural and perilobular ﬁbrosis
well as ﬁbroblastic foci with dense collagen ﬁbrosis (B) and smooth muscle cell proliferatio3. Discussion
The prognosis for MPA is poor even if corticosteroids and
immunosuppressant therapy are administered. Lung involvement,
such as diffuse alveolar hemorrhage and pulmonary ﬁbrosis (PF), is
an important prognostic factor. In a recent study of patients with
antineutrophil cytoplasmic antibodyeassociated vasculitis in
Japan, 47.4% and 11.5% of MPA cases were complicated with PF and
diffuse alveolar hemorrhage, respectively [1]. More recently, pre-
ceding idiopathic interstitial pneumonia was reported in MPA pa-
tients [2,3]. Initially, our patient had presented only with CPFE
comprising unclassiﬁed interstitial pneumonia and paraseptal
emphysema without vasculitis. Later, MPAwas diagnosed based on
the presence of glomerulonephritis and an elevated MPO-ANCA
titer.
In PF with MPA the most common ﬁndings on chest CT are
honeycombing, reticulonodular shadows, ground glass opacities,
traction bronchiectasis, and a usual interstitial pneumonia pattern
[2,4,5]. In the present case, chest CT showed paraseptal emphysema
in the bilateral upper lobes and reticular lesions with enlarged cysts
in the bilateral lower lobes, which had walls thinner than those
typical of honeycombing. Tzouvelekis et al. reported that 7 of 40
CPFE patients (17.5%) were positive for MPO-ANCA and that MPA
was diagnosed in 3 of these 7 patients [6].
CPFE was recently classiﬁed within the spectrum of smoking-
induced chronic lung diseases and is identiﬁed by chest CT ﬁnd-
ings of both upper lobe emphysema and lower lobe ﬁbrosis [8].
Cottin et al. studied patients with connective tissue disease who
also had CPFE. Some had rheumatoid arthritis or systemic sclerosis,
but none had MPA [9]. Occupational exposure to agents such as
silica [10], diffuse panbronchiolitis [11], and cigarette smoke may
be related to MPA development. In addition, Guilpain reported that
oxidative stressdespecially MPO-induced hypochlorous acidd
could trigger ﬁbroblast proliferation, resulting in PF [12].adjacent to relatively normal alveoli (usual interstitial pneumonia [UIP] pattern) (A), as
n in areas of dense collagen ﬁbrosis (C).
Fig. 4. Numerous macrophages with a few eosinophils were present in the alveolar lumen (DIP-like lesion) (A), and alveolar wall destruction with enlargement was seen in lung
parenchyma (B). Patchy ﬁbrotic lesions were also scattered around the terminal and respiratory bronchioles (C; arrow).
Fig. 5. Clinical course of the patient. MPO-ANCA: myeloperoxidase-antineutrophil cytoplasmic antibody; KL-6: Krebs von den Lungen-6; CCR: creatinine clearance.
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mens, PF with MPA is classiﬁed as having UIP or NSIP pattern with
lymphoid hyperplasia, bronchiolitis, and ﬁbrosis scattered around
the terminal and respiratory bronchioli [3,4,7]. However, these
ﬁndings are common in patients with connective tissue disease.
Thus, it is difﬁcult to differentiate MPA from idiopathic interstitial
pneumonia on the basis of radiologic and histologic ﬁndings.
In summary, some MPA cases are associated with CPFE. How-
ever, the pathogenesis of pulmonary ﬁbrosis in MPA remains un-
clear. Therefore, future studies should focus on the role of MPO-
ANCA to improve understanding of the clinicopathologic features
of CPFE with MPA.Acknowledgments
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